Results 141 to 150 of about 231,717 (193)

Causal Inference Challenges in Evaluating Baroreflex Activation Therapy for Transthyretin Amyloid Cardiomyopathy: A Critical Appraisal. [PDF]

JACC Case Rep
Humayun SH, Bareeqa SB.
europepmc   +1 more source

Patient Characteristics and Diagnosis of Transthyretin Amyloid Cardiomyopathy in Japan: Baseline Analysis of J-COSSA. [PDF]

JACC Asia
Endo J, Tanzawa K, Sato Y, Watanabe H, Takashio S, Kubo T, Minamisawa M, Tanaka H, Hashimoto T, Kawano H, Sakata K, Kanamori H, Tsuruda T, Fukata M, Kitagawa T, Noma T, Okada A, Kitai T, Yajima A, Iwataki M, Kondo H, Yamada Y, Ishii S, Izumiya Y, Ieda M, Kuwahara K, Nakamura K, Tahara N, Ueda M, Sekijima Y, Naiki H, Tsujita K, Kitaoka H, Inomata T.   +33 more
europepmc   +1 more source

Efficacy and Safety of Acoramidis in Japanese Adults With Symptomatic Transthyretin Amyloid Cardiomyopathy. [PDF]

Circ Rep
Endo J, Tsujita K, Izumi C, Yano T, Kitaoka H, Sekijima Y, Tahara N, Ishii S, Okumura T, Hashimoto T, Fukata M, Minamino T, Raizner A, Chen Y, Otsuka Y, Mercuri MF, Minamisawa M, Ando Y.   +17 more
europepmc   +1 more source

Vutrisiran in transthyretin amyloid cardiomyopathy: a structured review of the HELIOS-B trial and its secondary analyses. [PDF]

BMC Cardiovasc Disord
Niazai A, Zurmati BM, Shah ST, Hikmat G, Sohaib HU, Zainab HH, Faridzai MJK, Nisar MR.   +7 more
europepmc   +1 more source

Transthyretin amyloid cardiomyopathy-new data regarding epidemiology, diagnosis, and treatment. [PDF]

ESC Heart Fail
Tkaczyszyn M.
europepmc   +1 more source

Coexistence of hereditary transthyretin amyloid cardiomyopathy and sarcomeric hypertrophic cardiomyopathy: a multimodality imaging and genetic case report. [PDF]

Eur Heart J Case Rep
Negri F, Driussi M, Puppato M, Zuliani L, Imazio M.   +4 more
europepmc   +1 more source

SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy: A Promising Signal, but Not Yet the Final Word. [PDF]

Int J Heart Fail
Kim D.
europepmc   +1 more source

Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy. [PDF]

Circ Heart Fail
Masri A, Cappelli F, Davis MK, Fontana M, Garcia-Pavia P, Gillmore JD, Hanna M, Obici L, Solomon SD, Sperry BW, Tahara N, Waddington-Cruz M, Kristen AV, Falk RH, Shah SJ, Nativi-Nicolau J, Viney NJ, Yang Q, Chen J, Tsimikas S, Maurer MS.   +20 more
europepmc   +1 more source

Multimodality imaging characterization of Perugini scintigraphic grades in transthyretin amyloid cardiomyopathy: a single-center experience. [PDF]

J Cardiovasc Imaging
Bucius P, Zarambaite E, Lusaite K, Streckis M, Karuzas A, Plisiene J, Sakalyte G, Lapinskas T, Vajauskas D, Jankauskas A, Ereminiene E.   +10 more
europepmc   +1 more source

Fully Automated versus Human Echocardiogram Interpretation in Transthyretin Amyloid Cardiomyopathy: The SCAN-MP Study. [PDF]

J Am Soc Echocardiogr
McMenamin KJ, Teruya S, Slivnick J, Alreshq R, Ullah I, Fine D, Elzieny AA, Helmke S, Gallegos C, Miller EJ, Asch FM, Hasan S, Maurer MS, Ruberg FL.   +13 more
europepmc   +1 more source